Bliss GVS Pharma Share News - Latest Updates, Live News & More

Latest news about Bliss GVS Pharma

Bliss GVS Pharma Appoints Two Independent Directors for Five-Year Terms 3 days ago

Bliss GVS Pharma Limited has strengthened its board governance by appointing two experienced professionals as Independent Directors. The appointments of Mr. Vijayanarayanan Mahadevan, a Chartered Accountant with 35+ years of financial leadership experience, and Mr. Deepak Rameshchandra Shah, a Fellow Member of ICAI with 36+ years in taxation and audit, are effective for five years from April 03, 2026 to April 02, 2031, pending shareholder approval through postal ballot.

Bliss GVS Pharma Submits Q4FY26 SEBI Compliance Certificate for Securities Dematerialisation 3 days ago

Bliss GVS Pharma Clarifies Media Reports on Potential Anupam Rasayan Stake Acquisition Feb 13, 2026

Bliss GVS Pharma Publishes Q3FY26 Results in Newspapers Under SEBI Regulation 47 Feb 12, 2026

Bliss GVS Pharma Establishes Wholly Owned Subsidiary in Democratic Republic of Congo Jan 27, 2026

More news about Bliss GVS Pharma

23Dec 25

Bliss GVS Pharma Board Approves CEO S.N. Kamath's Appointment as Managing Director

Bliss GVS Pharma Limited's Board of Directors approved the appointment of current CEO S.N. Kamath as Managing Director for three consecutive years during a meeting held on December 23, 2025. The appointment, recommended by the Nomination and Remuneration Committee, is subject to shareholder approval through postal ballot and will be effective from the date of Special Resolution passage.

09Dec 25

Bliss GVS Pharma Boosts Employee Ownership with 66,380 New Equity Shares Under ESOP

Bliss GVS Pharma's ESOP Allotment Committee has approved the issuance of 66,380 new equity shares under its Employee Stock Option Plan (ESOP) 2019. The shares have a face value of Re. 1.00 and an exercise price of Rs. 43.00 per share. This allotment increases the total issued share capital to 10,57,88,972 shares, valued at Rs. 10,57,88,972.00. The newly allotted shares are subject to a 6-month lock-in period. This move represents a 0.63% increase in the company's outstanding shares and aims to enhance employee engagement and align their interests with the company's growth.

07Nov 25

Bliss GVS Pharma's Managing Director Gagan Harsh Sharma Steps Down

Gagan Harsh Sharma, Managing Director of Bliss GVS Pharma Limited, has resigned effective November 6, 2025, citing other professional commitments. He will also step down from various committee positions and directorships in subsidiary companies. The Board approved unaudited financial results for Q2 and H1 2025, and appointed Shreekrushna Joshi as Head – Legal and Senior Management Personnel.

07Nov 25

Bliss GVS Pharma Reports Q2 FY2026 Results and Appoints New Head-Legal

Bliss GVS Pharma announced its Q2 and H1 financial results for the period ending September 30, 2025. Standalone revenue from operations for Q2 was Rs 19,022.53 lakh, with a net profit of Rs 2,482.76 lakh. Consolidated revenue for Q2 stood at Rs 20,456.50 lakh, with a net profit of Rs 2,095.76 lakh. The company also appointed Mr. Shreekrushna Joshi as Head-Legal and Senior Management Personnel, effective November 6, 2025. Mr. Joshi brings over 15 years of experience in corporate legal, contract management, and secretarial compliance.

06Nov 25

Bliss GVS Pharma Grants 5.53 Lakh Stock Options to Employees at 72% Discount

Bliss GVS Pharma Limited has approved the grant of 553,000 stock options to eligible employees under its Employee Stock Options Plan 2019. The options are priced at Rs. 43.00 per share, a 72.05% discount to market price. The options will vest over four years in equal installments, with a six-month exercise period after vesting. Additionally, the company announced the resignation of Managing Director Mr. Gagan Harsh Sharma and the appointment of Mr. Shreekrushna Joshi as Head – Legal.

05Nov 25

Bliss GVS Pharma Expands Share Capital Through Employee Stock Option Allotment

Bliss GVS Pharma Limited has allotted 33,670 equity shares to eligible employees under its Employee Stock Option Plan 2019. The allotment, approved on November 5, 2025, increases the company's total issued shares from 10,56,88,923 to 10,57,22,592. Shares were issued at an exercise price of Rs. 43.00 per share and are subject to a six-month lock-in period until May 5, 2026. This move represents a 0.03% dilution for existing shareholders and aligns with the company's strategy to incentivize employees.

29Jul 25

Bliss GVS Pharma Reports Stellar Q1 FY2026 Results, Grants Employee Stock Options

Bliss GVS Pharma announced impressive Q1 FY2026 results with net profit doubling to ₹430.00 million and revenue increasing to ₹2,070.00 million. EBITDA rose to ₹413.00 million with a margin of 19.92%. The company also approved a grant of 268,000 stock options under its Employee Stock Options Plan 2019, with an exercise price of ₹43.00 per option/share and a four-year vesting period.

13May 25

Bliss GVS Pharma Reports Impressive Q4 Turnaround with 155.4 Crore Profit

Bliss GVS Pharma Ltd. has achieved a significant financial turnaround in Q4, reporting a consolidated net profit of 155.4 crore rupees compared to a 91.5 crore rupees loss in the same quarter last year. Revenue remained stable at 198.00 crore rupees year-over-year. The company's sequential growth shows profit increased from 23.80 crore rupees in the previous quarter. Despite stable revenue, Bliss GVS Pharma demonstrated improved operational efficiency with decreased interest costs, indicating better debt management.

12May 25

Bliss GVS Pharma Reports Mixed Q4 Results: Profit Turnaround Amid EBITDA Decline

Bliss GVS Pharma posted a consolidated net profit of ₹155.40 crore in Q4, reversing a loss of ₹91.50 crore from the previous year. Revenue remained stable at ₹1,980.00 crore. However, EBITDA decreased to ₹210.90 crore from ₹283.50 crore year-over-year, with EBITDA margin contracting to 10.65% from 14.31%. The results indicate a mixed performance with profit improvement but ongoing operational challenges.

15Apr 25

Bliss GVS Pharma's U.S. Partner Secures FDA Approval for Mesalamine Suppositories

Bliss GVS Pharma's U.S. partner, Rising Pharma Holdings, received FDA approval for Mesalamine Suppositories 1000 mg. The product targets a $29 million U.S. market. This approval strengthens Bliss GVS Pharma's portfolio of differentiated products for the U.S. market and demonstrates their in-house R&D capabilities.